NL-OMON36821已完成不适用
Effects of the Inspire(tm) Implantable Nerve Stimulation System on Obstructive Sleep Apnea (Inspire 4) - Inspire IV
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Suffer from moederate to severe OSA (AHI * 20) 2. Have failed or have not tolerated CPAP treatment 3. Age 22 or above 4. Willing and capable of providing informed consent and to return for all follow*up visits and sleep studies, including the evaluation procedures and filling out the questionnaires.
排除标准
- •1. Body Mass Index (BMI) of > 32
- •2. Surgical resection or radiation therapy for cancer or congenital malformations in the larynx, tongue, or throat (Note that some prior surgeries to remove obstructions related to obstructive sleep apnea are allowed; such as uvulopalatopharyngoplasty, tonsillectomy, or adenoidectomy)
- •3. Hypoglossal nerve palsy (obvious limited tongue movement, such as inability to protrude tongue, or unintended lateral deviation of the tongue when protruding).
- •4. Previous surgery within 12 weeks of scheduled implant performed on the soft tissue of the upper airway (e.g., uvula, soft palate or tonsils).
- •5. Obvious fixed upper airway obstructions (tumors, polyps, nasal obstruction)
- •6. Intrinsic neuromuscular disease, or other neurologic deficits (for examplee.g., multiple sclerosis, muscular dystrophy, Parkinson*s disease, amyotrophic lateral sclerosis, epilepsy, transient ischemic attack, or cerebrovascular accident)
- •7. Clinical evidence of severe chronic obstructive or restrictive pulmonary disease (for example chronic bronchitis, emphysema, pulmonary fibrosis), which may be) such as a normal or high FEV1/FVC with an FEV1 less than 50% of predicted, or severe chronic obstructive pulmonary disease (COPD) indicated by FEV1 (forced expiratory volume) < 50% predicted or FEV1/ FVC (forced vital capacity) ratio < 50%
- •8. Active, severe pulmonary vascular disease (0.7 as defined by the Global Initiative for example pulmonary arterial hypertension or pulmonary embolism)Chronic Obstructive Lung Disease (GOLD); Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease updated 2009
- •9. Moderate to severe pulmonary arterial hypertension as defined as Class III or higher as defined by the World Health Organization functional class, WHO FC) or documented by direct measurements of mean pulmonary arterial pressure by heart catheterization (PAPmean * 30 mmHg) or estimates of systolic pulmonary arterial pressure by echocardiogram (PAsys * 40 mmHg) [Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-47S]
- •10. Need for chronic supplemental oxygen therapy for any other reason, pO2 (partial pressure of oxygen) < 55 mm Hg
- •11. Currently receiving treatment for severe cardiac valvular dysfunction, NYHA Class III or IV heart failure, unstable angina or recent (< 6 month) myocardial infarction or severe cardiac arrhythmias
- •12. Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 6 months
- •13. Persistent uncontrolled hypertension (defined as systolic pressure *160 mm Hg or a diastolic pressure of * 100 mm Hg) despite medications
- •14. Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents patient compliance with the requirements of the investigational study testing
- •15. Other sleep disorders that confound functional assessments of sleepiness such as narcolepsy with cataplexy, insomnia, or sleep movement disorders such as restless leg syndrome or periodic limb movement producing sleep disturbances unrelated to obstructive sleep apnea
- •16. Taking medications that in the opinion of the consulting physician may alter consciousness, the pattern of respiration, or sleep architecture. Medications not given explicitly to impact nighttime sleep may be al
研究者
相似试验
已完成
3 期
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)Obstructive Sleep ApneaNCT01161420Inspire Medical Systems, Inc.929
招募中
不适用
The effect of non-invasive electrical stimulation for brain and peripheral nerves on motor performance and neural functioHealthy subjectsJPRN-UMIN000036852Yamagata Prefectural University of Health Sciences200
招募中
不适用
The effect of non-invasive neuromodulation of the pineal gland in healthy, adult malesSleepNeurological - Studies of the normal brain and nervous systemMental Health - Studies of normal psychology, cognitive function and behaviourACTRN12621000186853niversity of Otago20
已完成
不适用
on-pharmacological techniques for cognitive improvement in schizophreniaSchizophreniaRBR-69g952niversidade Federal de São Paulo
尚未招募
不适用
Comparing the effects of electrotherapy and nerve glides in management of low back pain radiating to legs.CTRI/2022/12/047885I